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April 23, 2013:1745–9Properly designed studies are needed to distinguish HFPEF
from the so-called EXIT syndrome.
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Reply
Although we accept that the diagnosis of heart failure and
preserved ejection fraction (HFPEF) is difficult and even contro-
versial, mainly because of the lack of a gold standard diagnostic
test, we believe that it is wrong to suggest that most or even many
patients in the trials we reviewed did not have heart failure. One of
the major premises of our report (1) was that the high mortality
and heart failure hospitalization rates among patients in these
trials, compared with patients of similar age and with similar
comorbidities (e.g., hypertension and diabetes), strongly supports
the view that the participants enrolled did have heart failure.
Moreover, as Dr. Pérez-Calvo and colleagues point out, left
ventricular hypertrophy (LVH) and left atrial (LA) enlargement
are now considered key echocardiographic findings supporting thediagnosis of HFPEF (2). These abnormalities were among the
inclusion criteria for the I-PRESERVE (Irbesartan in Heart
Failure with Preserved Systolic Function) trial, and in an echocar-
diographic substudy of this trial, 66% of participants had increased
LA size and up to 59% had LVH or concentric remodeling; 69%
had diastolic dysfunction (3).
Additionally, the new European guidelines (2) also stress the
mportance of natriuretic peptides in the diagnosis of HF. A “rule-
ut” cutoff of 125 pg/ml is suggested for N-terminal pro–B-type
atriuretic peptide (NT-proBNP) (although it is recognized that
atients with HFPEF may have lower levels). The median NT-
roBNP in I-PRESERVEwas 341 pg/ml (interquartile range: 135 to
74 pg/ml) (4), demonstrating that around three-quarters of patients
n I-PRESERVE exceeded this diagnostic cutpoint, although NT-
roBNP levels decreased with treatment.
Based on these observations, we believe that the majority of
atients enrolled in I-PRESERVE (and probably the other
FPEF trials) would meet today’s diagnostic criteria for HFPEF.
o assume that the patients in these studies had an alternative
rimary diagnosis is highly speculative.
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